Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. Separation of the antithrombotic effect and bleeding for candidate drug AZD1283

Journal of Medicinal Chemistry

Volumn 56, Issue 17, 2013, Pages 7015-7024

  Bach, Peter ^a   Antonsson, Thomas ^a   Bylund, Ruth ^a   Björkman, Jan Arne ^a   Österlund, Krister ^a   Giordanetto, Fabrizio ^a   Van Giezen, J J J ^a   Andersen, Søren M ^a   Zachrisson, Helen ^a   Zetterberg, Fredrik ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; AZD 1283; AZETIDINE DERIVATIVE; LEAD; PIPERIDINE DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; SULFONAMIDE; UNCLASSIFIED DRUG;

ARTICLE; BLEEDING TIME; DRUG CLEARANCE; DRUG POTENCY; IN VIVO STUDY; NONHUMAN; PROCESS OPTIMIZATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DOGS; HUMANS; NIACIN; RECEPTORS, PURINERGIC P2Y12; SULFONAMIDES; THROMBOSIS;

EID: 84884224776     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400820m     Document Type: Article

References (31)

1. Michelson, A. D. Antiplatelet therapies for the treatment of cardiovascular disease Nat. Rev. Drug Discovery 2010, 9, 154-169
2. Broos, K.; Feys, H. B.; De Meyer, S. F.; Vanhoorelbeke, K.; Deckmyn, H. Platelets at work in primary hemostasis Blood Rev. 2011, 25, 155-167
3. Hollopeter, G.; Jantzen, H.-M.; Vincent, D.; Li, G.; England, L.; Ramakrishnan, V.; Yang, R.-B.; Nurden, P.; Nurden, A.; Julius, D.; Conley, P. B. Identification of the platelet ADP receptor targeted by antithrombotic drugs Nature 2001, 409, 202-207
4. Abbracchio, M. P.; Burnstock, G.; Boeynaems, J. M.; Barnard, E. M.; Boyer, J. L.; Kennedy, C.; Knight, G. E.; Fumagalli, M.; Gachet, C.; Jacobson, K. A.; Weisman, G. A. International Union of Pharmacology LVIII: Update on the P2Y G protein-coupled nucleotide receptors: From molecular mechanisms and pathophysiology to therapy Pharmacol. Rev. 2006, 58, 281-341
5. Li, Z.; Delaney, K.; O'Brien, K. A.; Du, X. Signaling during platelet adhesion and activation Arterioscler., Thromb., Vasc. Biol. 2010, 30, 2341-2349
6. 12 receptor Curr. Pharm. Des. 2006, 12, 1255-1259
7. Mackman, N. Triggers, targets and treatments for thrombosis Nature 2008, 451, 914-918
8. Savi, P.; Pereillo, J. M.; Uzabiaga, M. F.; Combalbert, J.; Picard, C.; Maffrand, J. P.; Pascal, M.; Herbert, J. M. Identification and biological activity of the active metabolite of clopidogrel Thromb. Haemostasis 2000, 84, 891-896
9. Sugidachi, A.; Ogawa, T.; Kurihara, A.; Hagihara, K.; Jakubowski, J. A.; Hashimoto, M.; Niitsu, Y.; Asai, F. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite J. Thromb. Haemostasis 2007, 5, 1545-1551
10. Yusuf, S.; Zhao, F.; Mehta, S. R.; Chrolavicius, S.; Tognoni, G.; Fox, K. K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N. Engl. J. Med. 2001, 345, 494-501
11. 12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation J. Thromb. Haemostasis 2009, 7, 1556-1565
12. 12 binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis Thromb. Res. 2009, 124, 565-571
13. 12 receptor antagonist for the prevention of thrombosis Bioorg. Med. Chem. Lett. 2007, 17, 6013-6018
14. 12 antagonists Semin. Thromb. Hemostasis 2005, 31, 195-204
15. 12 antagonists for inhibition of platelet aggregation J. Med. Chem. 2010, 53, 2010-2037
16. 12 antagonists for inhibition of platelet aggregation Bioorg. Med. Chem. Lett. 2010, 20, 1388-1394
17. 12 antagonists for inhibition of platelet aggregation Bioorg. Med. Chem. Lett. 2009, 19, 4657-4663
18. 12 antagonists for inhibition of platelet aggregation Bioorg. Med. Chem. Lett. 2009, 19, 6148-6156
19. 12 platelet aggregation inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 5919-5923
20. 12 receptors J. Med. Chem. 2009, 52, 3784-3793
21. 12 receptor Bioorg. Med. Chem. Lett. 2008, 18, 2167-2171
22. 12 receptor J. Med. Chem. 2008, 51, 1007-1025
23. 12 antagonists based on a phenylpyrazole glutamic acid piperazine backbone J. Med. Chem. 2012, 55, 8615-8629
24. 12 receptor Bioorg. Med. Chem. Lett. 2011, 21, 2877-2881
25. 12 receptor Eur. J. Med. Chem. 2013, 65, 360-375
26. Ellis, D. Racemisation-free synthesis of chiral acylsulfonamides Tetrahedron: Asymmetry 2001, 12, 1589-1593
27. Fox, S. C.; Burgess-Wilson, M.; Heptinstall, S.; Mitchell, J. R. A. Platelet aggregation in whole blood determined using the Ultra-Flo 100 platelet counter Thromb. Haemostasis 1982, 48 (3) 327-329
28. a > 80%). See also: Ungell, A.-L.; Karlsson, J. Cell cultures in drug discovery: an industrial perspective In Drug Bioavailability. Estimation of Solubility, Permeability, Absorption and Bioavailability; van de Waterbeemd, H.; Lennernäs, H.; Artursson, P., Eds.; Wiley-VCH Verlag GmbH & Co.: Weinheim, Germany, 2003, Chapter 5 pp 90-131.
29. Hansch, C.; Leo, A.; Hoekman, D. Exploring QSAR, Vol 2: Hydrophobic, Electronic, and Steric Constants; American Chemical Society: Washington, DC, 1995.
30. Smith, D. A.; Di, L.; Kerns, E. H. The effect of plasma protein binding on in vivo efficacy: Misconceptions in drug discovery Nat. Rev. Drug Discovery 2010, 9, 929-939
31. Baskin, J. M.; Wang, Z. A mild, convenient synthesis of sulfinic acid salts and sulfonamides from alkyl and aryl halides Tetrahedron Lett. 2002, 43, 8479-8483